Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).

Trial Profile

Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Maraviroc (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms ROCnRAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Sep 2015 Results published in the Journal of Antimicrobial Chemotherapy.
    • 30 Apr 2013 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top